Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Identifieur interne : 001422 ( PubMed/Curation ); précédent : 001421; suivant : 001423Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Auteurs : Shabir A. Madhi [Afrique du Sud] ; Sylvia Dittmer ; Locadiah Kuwanda ; Marietjie Venter ; Haseena Cassim ; Erica Lazarus ; Teena Thomas ; Afaaf Liberty ; Florette Treurnich ; Clare L. Cutland ; Adriana Weinberg ; Avy ViolariSource :
- AIDS (London, England) [ 1473-5571 ] ; 2013.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (immunologie), Enfant d'âge préscolaire, Excrétion virale, Femelle, Grippe humaine (immunologie), Grippe humaine (virologie), Grippe humaine (épidémiologie), Hospitalisation, Humains, Mâle, Méthode en double aveugle, Nourrisson, Numération des lymphocytes CD4, Phylogénie, Pneumopathie infectieuse (immunologie), Pneumopathie infectieuse (virologie), Pneumopathie infectieuse (épidémiologie), République d'Afrique du Sud (épidémiologie), Résultat thérapeutique, Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H1N1 du virus de la grippe A (isolement et purification), Sous-type H3N2 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (isolement et purification), Séropositivité VIH (immunologie), Séropositivité VIH (épidémiologie), Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Virus de la grippe A (immunologie), Virus de la grippe A (isolement et purification), Virus influenza B (immunologie), Virus influenza B (isolement et purification), Études de suivi.
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Anticorps antiviraux, Grippe humaine, Pneumopathie infectieuse, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Séropositivité VIH, Vaccins antigrippaux, Virus de la grippe A, Virus influenza B.
- isolement et purification : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus de la grippe A, Virus influenza B.
- virologie : Grippe humaine, Pneumopathie infectieuse.
- épidémiologie : Grippe humaine, Pneumopathie infectieuse, République d'Afrique du Sud, Séropositivité VIH.
- Enfant d'âge préscolaire, Excrétion virale, Femelle, Hospitalisation, Humains, Mâle, Méthode en double aveugle, Nourrisson, Numération des lymphocytes CD4, Phylogénie, Résultat thérapeutique, Tests d'inhibition de l'hémagglutination, Études de suivi.
- Wicri :
- geographic : Afrique du Sud.
English descriptors
- KwdEn :
- Antibodies, Viral (immunology), CD4 Lymphocyte Count, Child, Preschool, Double-Blind Method, Female, Follow-Up Studies, HIV Seropositivity (epidemiology), HIV Seropositivity (immunology), Hemagglutination Inhibition Tests, Hospitalization, Humans, Infant, Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza A Virus, H3N2 Subtype (immunology), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza A virus (immunology), Influenza A virus (isolation & purification), Influenza B virus (immunology), Influenza B virus (isolation & purification), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (virology), Male, Phylogeny, Pneumonia (epidemiology), Pneumonia (immunology), Pneumonia (virology), South Africa (epidemiology), Treatment Outcome, Virus Shedding.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines.
- geographic , epidemiology : South Africa.
- epidemiology : HIV Seropositivity, Influenza, Human, Pneumonia.
- immunology : HIV Seropositivity, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A virus, Influenza B virus, Influenza, Human, Pneumonia.
- isolation & purification : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A virus, Influenza B virus.
- virology : Influenza, Human, Pneumonia.
- CD4 Lymphocyte Count, Child, Preschool, Double-Blind Method, Female, Follow-Up Studies, Hemagglutination Inhibition Tests, Hospitalization, Humans, Infant, Male, Phylogeny, Treatment Outcome, Virus Shedding.
Abstract
HIV-infected children are at heightened risk for severe influenza illness; however, there is no study on the efficacy or effectiveness of influenza vaccine in these children. We evaluated the safety, immunogenicity, and efficacy of nonadjuvanted, trivalent inactivated influenza vaccine (TIV) against confirmed seasonal influenza virus illness in HIV-infected children.
DOI: 10.1097/QAD.0b013e32835ab5b2
PubMed: 23032417
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001422
Links to Exploration step
pubmed:23032417Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.</title><author><name sortKey="Madhi, Shabir A" sort="Madhi, Shabir A" uniqKey="Madhi S" first="Shabir A" last="Madhi">Shabir A. Madhi</name><affiliation wicri:level="1"><nlm:affiliation>National Institute of Communicable Diseases, Centre for Respiratory and Meningitis Diseases, Sandringham, South Africa. shabirm@nicd.ac.za</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>National Institute of Communicable Diseases, Centre for Respiratory and Meningitis Diseases, Sandringham</wicri:regionArea></affiliation></author><author><name sortKey="Dittmer, Sylvia" sort="Dittmer, Sylvia" uniqKey="Dittmer S" first="Sylvia" last="Dittmer">Sylvia Dittmer</name></author><author><name sortKey="Kuwanda, Locadiah" sort="Kuwanda, Locadiah" uniqKey="Kuwanda L" first="Locadiah" last="Kuwanda">Locadiah Kuwanda</name></author><author><name sortKey="Venter, Marietjie" sort="Venter, Marietjie" uniqKey="Venter M" first="Marietjie" last="Venter">Marietjie Venter</name></author><author><name sortKey="Cassim, Haseena" sort="Cassim, Haseena" uniqKey="Cassim H" first="Haseena" last="Cassim">Haseena Cassim</name></author><author><name sortKey="Lazarus, Erica" sort="Lazarus, Erica" uniqKey="Lazarus E" first="Erica" last="Lazarus">Erica Lazarus</name></author><author><name sortKey="Thomas, Teena" sort="Thomas, Teena" uniqKey="Thomas T" first="Teena" last="Thomas">Teena Thomas</name></author><author><name sortKey="Liberty, Afaaf" sort="Liberty, Afaaf" uniqKey="Liberty A" first="Afaaf" last="Liberty">Afaaf Liberty</name></author><author><name sortKey="Treurnich, Florette" sort="Treurnich, Florette" uniqKey="Treurnich F" first="Florette" last="Treurnich">Florette Treurnich</name></author><author><name sortKey="Cutland, Clare L" sort="Cutland, Clare L" uniqKey="Cutland C" first="Clare L" last="Cutland">Clare L. Cutland</name></author><author><name sortKey="Weinberg, Adriana" sort="Weinberg, Adriana" uniqKey="Weinberg A" first="Adriana" last="Weinberg">Adriana Weinberg</name></author><author><name sortKey="Violari, Avy" sort="Violari, Avy" uniqKey="Violari A" first="Avy" last="Violari">Avy Violari</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23032417</idno><idno type="pmid">23032417</idno><idno type="doi">10.1097/QAD.0b013e32835ab5b2</idno><idno type="wicri:Area/PubMed/Corpus">001422</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001422</idno><idno type="wicri:Area/PubMed/Curation">001422</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001422</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.</title><author><name sortKey="Madhi, Shabir A" sort="Madhi, Shabir A" uniqKey="Madhi S" first="Shabir A" last="Madhi">Shabir A. Madhi</name><affiliation wicri:level="1"><nlm:affiliation>National Institute of Communicable Diseases, Centre for Respiratory and Meningitis Diseases, Sandringham, South Africa. shabirm@nicd.ac.za</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>National Institute of Communicable Diseases, Centre for Respiratory and Meningitis Diseases, Sandringham</wicri:regionArea></affiliation></author><author><name sortKey="Dittmer, Sylvia" sort="Dittmer, Sylvia" uniqKey="Dittmer S" first="Sylvia" last="Dittmer">Sylvia Dittmer</name></author><author><name sortKey="Kuwanda, Locadiah" sort="Kuwanda, Locadiah" uniqKey="Kuwanda L" first="Locadiah" last="Kuwanda">Locadiah Kuwanda</name></author><author><name sortKey="Venter, Marietjie" sort="Venter, Marietjie" uniqKey="Venter M" first="Marietjie" last="Venter">Marietjie Venter</name></author><author><name sortKey="Cassim, Haseena" sort="Cassim, Haseena" uniqKey="Cassim H" first="Haseena" last="Cassim">Haseena Cassim</name></author><author><name sortKey="Lazarus, Erica" sort="Lazarus, Erica" uniqKey="Lazarus E" first="Erica" last="Lazarus">Erica Lazarus</name></author><author><name sortKey="Thomas, Teena" sort="Thomas, Teena" uniqKey="Thomas T" first="Teena" last="Thomas">Teena Thomas</name></author><author><name sortKey="Liberty, Afaaf" sort="Liberty, Afaaf" uniqKey="Liberty A" first="Afaaf" last="Liberty">Afaaf Liberty</name></author><author><name sortKey="Treurnich, Florette" sort="Treurnich, Florette" uniqKey="Treurnich F" first="Florette" last="Treurnich">Florette Treurnich</name></author><author><name sortKey="Cutland, Clare L" sort="Cutland, Clare L" uniqKey="Cutland C" first="Clare L" last="Cutland">Clare L. Cutland</name></author><author><name sortKey="Weinberg, Adriana" sort="Weinberg, Adriana" uniqKey="Weinberg A" first="Adriana" last="Weinberg">Adriana Weinberg</name></author><author><name sortKey="Violari, Avy" sort="Violari, Avy" uniqKey="Violari A" first="Avy" last="Violari">Avy Violari</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (immunology)</term><term>CD4 Lymphocyte Count</term><term>Child, Preschool</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>HIV Seropositivity (epidemiology)</term><term>HIV Seropositivity (immunology)</term><term>Hemagglutination Inhibition Tests</term><term>Hospitalization</term><term>Humans</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza A Virus, H3N2 Subtype (immunology)</term><term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term><term>Influenza A virus (immunology)</term><term>Influenza A virus (isolation & purification)</term><term>Influenza B virus (immunology)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Phylogeny</term><term>Pneumonia (epidemiology)</term><term>Pneumonia (immunology)</term><term>Pneumonia (virology)</term><term>South Africa (epidemiology)</term><term>Treatment Outcome</term><term>Virus Shedding</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (immunologie)</term><term>Enfant d'âge préscolaire</term><term>Excrétion virale</term><term>Femelle</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Hospitalisation</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Nourrisson</term><term>Numération des lymphocytes CD4</term><term>Phylogénie</term><term>Pneumopathie infectieuse (immunologie)</term><term>Pneumopathie infectieuse (virologie)</term><term>Pneumopathie infectieuse (épidémiologie)</term><term>République d'Afrique du Sud (épidémiologie)</term><term>Résultat thérapeutique</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Sous-type H3N2 du virus de la grippe A (immunologie)</term><term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term><term>Séropositivité VIH (immunologie)</term><term>Séropositivité VIH (épidémiologie)</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Virus de la grippe A (immunologie)</term><term>Virus de la grippe A (isolement et purification)</term><term>Virus influenza B (immunologie)</term><term>Virus influenza B (isolement et purification)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Seropositivity</term><term>Influenza, Human</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Grippe humaine</term><term>Pneumopathie infectieuse</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Séropositivité VIH</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Seropositivity</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A virus</term><term>Influenza B virus</term><term>Influenza, Human</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie infectieuse</term><term>République d'Afrique du Sud</term><term>Séropositivité VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>CD4 Lymphocyte Count</term><term>Child, Preschool</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Hemagglutination Inhibition Tests</term><term>Hospitalization</term><term>Humans</term><term>Infant</term><term>Male</term><term>Phylogeny</term><term>Treatment Outcome</term><term>Virus Shedding</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Enfant d'âge préscolaire</term><term>Excrétion virale</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Nourrisson</term><term>Numération des lymphocytes CD4</term><term>Phylogénie</term><term>Résultat thérapeutique</term><term>Tests d'inhibition de l'hémagglutination</term><term>Études de suivi</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique du Sud</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">HIV-infected children are at heightened risk for severe influenza illness; however, there is no study on the efficacy or effectiveness of influenza vaccine in these children. We evaluated the safety, immunogenicity, and efficacy of nonadjuvanted, trivalent inactivated influenza vaccine (TIV) against confirmed seasonal influenza virus illness in HIV-infected children.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23032417</PMID><DateCreated><Year>2013</Year><Month>01</Month><Day>07</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.</ArticleTitle><Pagination><MedlinePgn>369-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e32835ab5b2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">HIV-infected children are at heightened risk for severe influenza illness; however, there is no study on the efficacy or effectiveness of influenza vaccine in these children. We evaluated the safety, immunogenicity, and efficacy of nonadjuvanted, trivalent inactivated influenza vaccine (TIV) against confirmed seasonal influenza virus illness in HIV-infected children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A double-blind, placebo-controlled trial was undertaken in Johannesburg in 2009. Four hundred and ten children were randomized to two doses of TIV or placebo 1 month apart. Nasopharyngeal aspirates obtained at respiratory illness visits were tested by influenza-specific reverse transcriptase-PCR (RT-PCR). Vaccine immunogenicity was evaluated by hemagglutinin inhibition (HAI) assay. Influenza isolates were sequenced and evaluated in maximum likelihood phylogenetic analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, the median age of participants was 23.8 months and their median CD4% was 33.5. Ninety-two percent of enrolees were on antiretroviral therapy. Among children receiving both doses of vaccine/placebo, confirmed seasonal influenza illness occurred in 13 (all H3N2) of 205 TIV recipients and 17 (15 H3N2 and two influenza B) of 200 placebo recipients with vaccine efficacy of 17.7% (95% confidence interval <0-62.4%). The proportion of TIV recipients who seroconverted after second dose against vaccine strains of H1N1, H3N2, and influenza B were 47.5, 50.0, and 40.0%, compared to 4.7, 11.6, and 0%, respectively among placebo recipients. There were no TIV-related serious adverse events. Sequence analysis of wild-type H3N2 strains indicated drift from the H3N2 vaccine strain.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Poor immunogenicity of TIV, coupled with drift of circulating H3N2 wild-type compared to vaccine strain, may explain the lack of efficacy of TIV in young HIV-infected children. Alternate TIV vaccine schedules or formulations warrant evaluation for efficacy in HIV-infected children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madhi</LastName><ForeName>Shabir A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>National Institute of Communicable Diseases, Centre for Respiratory and Meningitis Diseases, Sandringham, South Africa. shabirm@nicd.ac.za</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dittmer</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kuwanda</LastName><ForeName>Locadiah</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Venter</LastName><ForeName>Marietjie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cassim</LastName><ForeName>Haseena</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lazarus</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Teena</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liberty</LastName><ForeName>Afaaf</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Treurnich</LastName><ForeName>Florette</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cutland</LastName><ForeName>Clare L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Violari</LastName><ForeName>Avy</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006679" MajorTopicYN="N">HIV Seropositivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23032417</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e32835ab5b2</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001422 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001422 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23032417
|texte= Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23032417" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |